Wegovy rebound weight gain: what the evidence actually shows

The myth that rebound means the treatment 'stopped working'

One of the most persistent misunderstandings about Wegovy rebound is the idea that weight coming back proves the medicine was not effective. The opposite is closer to the truth. The weight loss in clinical trials was real, and it was driven by a sustained change in appetite signalling while semaglutide was present in the body. When the medicine is stopped, the body's hunger hormones and gastric-emptying rate drift back towards their pre-treatment baseline. That is physiology, not failure.

Obesity is a chronic condition with a strong biological component, as the NHS explains in its overview of obesity. The same logic applies here as it does with blood pressure medication or statins: the underlying condition does not disappear because treatment is paused. Rebound weight gain is therefore less a statement about what Wegovy does, and more a statement about what obesity is.

Knowing this upfront matters. People who go in expecting a finite course, like a course of antibiotics, are the ones most likely to feel blindsided when the scales move after stopping. The ones who make the most lasting progress tend to treat the lifestyle changes built during treatment, the eating patterns, the activity habits, the relationship with hunger, as the part worth protecting.

What the data say about the scale and speed of rebound

The extension phase of the STEP 1 trial is the clearest window into Wegovy rebound weight gain we have. After 68 weeks on semaglutide 2.4mg, participants had lost an average of around 15% of their body weight. Over the following 52-week off-treatment period, about two-thirds of that loss was regained. By the end of the observation window, body weight was converging back towards pre-treatment levels for many participants.

The regain was fastest in the first few months after stopping, then slowed. This pattern is consistent with what happens to appetite: the effect of semaglutide on hunger dissipates within weeks of the last dose, and caloric intake tends to rise before new habits have time to compensate. People who had made the most concrete changes to their diet and activity during treatment showed slower regain, though the data do not suggest lifestyle changes alone are sufficient to prevent it entirely for most people.

If you are currently on Wegovy 1 and want a sense of what a realistic pace of progress looks like at that stage, this page sets out what clinical evidence suggests. And if you want to understand how many pounds a week you can realistically lose on Wegovy, that broader picture is worth reading alongside the rebound data. If progress has slowed, slower loss on semaglutide is a separate, common concern worth understanding on its own terms.

What you can do to reduce rebound risk

There is no guaranteed way to avoid rebound entirely, and anyone who tells you otherwise is overselling. But the evidence points to several factors that help.

First, do not stop abruptly without a clinical conversation. There is no pharmacological reason Wegovy must be tapered (unlike some other medicines), but stopping without a plan for what comes next is the fastest route to rapid regain. A prescriber can help you think through the timing, whether that means a structured break or a longer-term continuation strategy.

Second, the lifestyle structures built during treatment are the ones worth measuring before stopping. A quick habit to build now: once a week, write down what you actually ate the day before, honestly. Most people find this takes under a minute, and it makes the transition from appetite-suppressed to appetite-returned much less surprising. It is a habit our prescribers suggest to patients considering a pause in treatment.

Third, consider the evidence on long-term use. NICE's appraisal of semaglutide, published as TA875, recommends it within a structured programme. Patients who have moved through their dose escalation and are weighing up whether to continue will find that Wegovy 2 covers what ongoing treatment at the maintenance dose looks like. For people exploring whether semaglutide fits their longer-term picture, or whether another medicine might suit them better, that conversation starts with an assessment, not a prescription pad.

Private treatment at nume's consultation page involves clinical review before every repeat order, which means your prescriber is seeing your progress data regularly and can flag if a change in approach is warranted. There are no automatic renewals and no auto-dispatch — each order is looked at individually by a GPhC-registered prescriber.